



ANNOUNCEMENT

We are delighted to welcome **Dr. Elizabeth Quackenbush** as our Chief Medical Officer, strengthening our team at a pivotal moment in Ability's journey.

Betsy is a physician scientist with over 20 years of leadership in drug development across preclinical discovery and late-stage clinical trials. She trained in Internal Medicine and Clinical Genetics at Beth Israel and Boston Children's Hospital, followed by a fellowship at Dana-Farber Cancer Institute. Over her career, Elizabeth has held senior roles at Merck, Roche, Agennix, Celldex, and Elstar Therapeutics, with a focus on immuno-oncology, T-cell engagers, and gene therapies for rare diseases.

Her appointment marks an important milestone as Ability moves closer to the clinic. At Ability, we are advancing a pipeline of next-generation logic-gated antibody biotherapeutics powered by our AbiLeap™ platform, designed to transform patient care in cancer and immunology. With Betsy's expertise in translational medicine, we are well positioned to bring these innovations into the clinic and closer to patients.

Welcoming our new Chief Medical Officer

Dr. Elizabeth Quackenbush



Strengthening our team at a pivotal moment to advance next-generation logic-gated antibody therapeutics for patients

